USA Shipped · Chino, California
Research Use Only Products are for laboratory research only, not for human or animal consumption. Research Compliance
Research Reference

Cagrilintide 5mg Research Reference

Complete research reference and reconstitution guide for Cagrilintide 5mg.

Research Use Only Reconstitution Math Storage Reference

Quick Reference

Vial Amount
5mg
CoreVials Standard Mix
Add 1.67 mL (167 units) BAC Water
Final Concentration
2.99 mg/mL
Easy Reference
10 units = 0.30 mg
Storage
Refrigerate after reconstitution

This page is for research-use-only educational reference and measurement math. It is not medical, veterinary, dosing, administration, or treatment guidance. Products are not for human or animal consumption.

On this page

How This Works

Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly measurement[6][11].

CoreVials Standard Mix

For a 5mg vial Add 1.67 mL (167 units) BAC Water
Final concentration 2.99 mg/mL

After mixing (U-100 syringe reference)

  • 5 units=0.15 mg
  • 10 units=0.3 mg
  • 20 units=0.6 mg

These are example measurement calculations only. They are not dosing, administration, medical, or veterinary guidance.

Other Mix Options
BAC Added Final Concentration Dose per 10 units
1.67 mL (167 units) CoreVials Standard Mix 2.99 mg/mL 0.30 mg
1.67 mL (167 units) 5.99 mg/mL 0.60 mg

Supply Planning

Products commonly paired for research preparation:

  • Cagrilintide 5mg Research Reference
  • BAC Water
  • Cryo labels
  • Storage case

References

The Lancet (2021)
— Once‑weekly cagrilintide for weight management: phase 2 dose‑finding trial (Lau et al.)

Int J Mol Sci (2024)
— Amylin, another important neuroendocrine hormone for research model of diabesity

PMC (2022)
— Mediators of amylin action in metabolic control

The Lancet (2021)
— Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks

N Engl J Med (2025)
— REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity

The Lancet (2021)
— Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.)

J Med Chem (2021)
— Development of cagrilintide: a long‑acting amylin analogue

Brain Res Rev (2005)
— Pancreatic amylin as a centrally acting satiating hormone

PMC (2006)
— Pancreatic signals controlling food intake: insulin, glucagon, and amylin

PMC (2016)
— Amylin‑mediated control of glycemia, energy balance, and cognition

PMC (2024)
— Clinical pharmacokinetics of semaglutide: systematic review (includes cagrilintide PK data)

N Engl J Med (2025)
— REDEFINE 2: Cagrilintide–semaglutide in adults with overweight/obesity and type 2 diabetes

CDC
— Vaccine preparation: handling reference and site guidance

CDC (PDF)
— You Call the Shots: measurement diagram and best practices

PMC (2019)
— drug delivery: pharmacologic considerations and techniques

American College of Cardiology (2025)
— REDEFINE 1 and REDEFINE 2 journal scan summary

The Lancet (2023)
— Efficacy and safety of CagriSema in type 2 diabetes: phase 2 trial (Frias et al.)

PMC (2024)
— Efficacy and safety of cagrilintide and CagriSema: systematic review and meta‑analysis

Research Use Notice

This page is research-use-only educational reference and measurement math. It is not medical, veterinary, dosing, administration, or treatment guidance. Products are not for human or animal consumption.

Need research supplies?

High-purity peptides and lab essentials with batch-level COA transparency.

Research Use Only Products are for laboratory research only, not for human or animal consumption. Research Compliance